New Findings on Insulin Resistance from St. Vincent's University Hospital Summarized [Metabolic Complications Associated With Use of Integrase Strand Transfer Inhibitors (Insti) for the Treatment of Hiv-1 Infection: Focus On Weight Changes,...].

A recent study conducted at St. Vincent's University Hospital in Dublin, Ireland, examined the effects of treatment with Integrase Strand Transfer Inhibitors (InSTI) on metabolic health in people with HIV. The study found that InSTI had a mild to moderate effect on weight gain, particularly in certain groups such as women, people of Black African ethnicity, those with lower socioeconomic status, and older individuals. However, InSTI were found to have a relatively safe profile in terms of lipid parameters and bone health compared to other antiretroviral therapies. The study concluded that while InSTI remain the preferred treatment option for most people with HIV due to their high efficacy and tolerability, an individualized approach to treatment should be used to avoid negative outcomes in populations at higher risk of metabolic complications. [Extracted from the article]

Copyright of Diabetes Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)